Research programme: MTAP-deleted cancer therapeutics - Agios/Celgene

Drug Profile

Research programme: MTAP-deleted cancer therapeutics - Agios/Celgene

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein-arginine N-methyltransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 14 Feb 2018 Agios Pharmaceuticals has pending patents for MTAP-deleted cancer therapeutics in countries worldwide
  • 26 Dec 2017 Agios Pharmaceuticals plans a dose-escalation phase I trial of AG 270 for MTAP-deleted Cancer (Late-stage disease, Second-line therapy or greater) in USA, France and Spain in the first quarter of 2018 (PO) (NCT03435250)
  • 04 May 2017 Agios intends to submit IND application for AG 270 to the US FDA for Cancer by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top